-
If you purchased shares of Dynavax Technologies Corporation (NASDAQ: DVAX), you might have certain options and should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Lawsuit Overview
Settlement Overview
You must register to view and download the Settlement Notice and Settlement Proof.
November 6, 2017 - The court ordered the authorization of the distribution of the net settlement fund.
February 10, 2017 - The court entered the order approving the motion for attorneys’ fees and expenses.
February 6, 2017 - The court approved the settlement and dismissed the action with prejudice.
October 14, 2016 - The court preliminarily approved the settlement.
September 7, 2016 - Parties filed a stipulation of settlement.
October 10, 2014 - The defendants filed a motion to dismiss.
September 10, 2014 - The lead plaintiff filed a third amended complaint.
June 6, 2014 - The defendants filed motions to dismiss.
April 7, 2014 - The lead plaintiff filed a second amended consolidated complaint.
January 10, 2014 - The defendants filed a motion to dismiss.
November 12, 2013 - The lead plaintiff filed an amended consolidated complaint.
September 27, 2013 - The lead plaintiff and lead counsel were appointed.
August 22, 2013 - All cases were consolidated.
August 19, 2013 - A lead plaintiff motion was filed.
June 26, 2013 - Another investor filed a complaint.
June 18, 2013 - An investor in shares of Dynavax Technologies Corporation (NASDAQ: DVAX) filed a lawsuit in the U.S. District Court for the Northern District of California against Dynavax Technologies Corporation over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between April 26, 2012 and June 10, 2013.
According to the complaint the plaintiff alleges on behalf of purchasers Dynavax Technologies Corporation (NASDAQ: DVAX) common stock during the period between April 26, 2012 and June 10, 2013, that Dynavax Technologies Corporation and certain of its officers and directors violated the Securities Exchange Act of 1934 by disseminating allegedly false and misleading statements to the investing public about the viability of HEPLISAV, an investigational adult hepatitis B vaccine.
Dynavax Technologies Corporation reported that its Total Revenue declined from $23.95 million in 2010 to $21.61 million in 2011 and that its Net Loss decreased from $57.31 million in 2010 to $48.60 million in 2011. For the first three quarters in 2012 Dynavax Technologies Corporation reported a combined nine months Total Revenue of $7.9 million with a combined nine months Net Loss of $49.40 million.
Shares of Dynavax Technologies Corporation increased from $1.83 per share in October 2011 to as high as $5.15 per share in April, respectively $4.91 per shares in October 2012.
Then on February 25, 2013, Dynavax Technologies Corporation announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (“FDA” or Agency) regarding its Biologic License Application for HEPLISAV, an investigational adult hepatitis B vaccine. Among other things, the FDA specified in the complete response letter, that the indication in adults 18-70 years of age cannot be approved without further evaluation of safety in this broad age group. Shares of Dynavax Technologies Corporation declined from $3.118 per share on February 22, 2013 to $1.87 per share on February 25, 2013.
Then on June 10, 2013, Dynavax Technologies Corporation reported that it recently concluded a meeting with the U.S. Food and Drug Administration regarding its Biologic License Application for HEPLISAV. Shares of Dynavax Technologies Corporation (NASDAQ: DVAX) fell from $2.55 per share on June 6, 2013 to $1.04 per share on June 18, 2013.